NX210 is a patented peptide deduced from the thrombospondin repeat domains (TSRs) of the SCO-spondin. This is a first-in class multi-functional agent able to prevents neural cell death and to promote neurite outgrowth. Our data show that NX210 is able to promote neurite fasciculation and axonogenesis in a dose-dependent manner [1; 2] as well as to protect neurons against insults .
In vivo, NX210 has been shown to promote nerve fiber regrowth and the recovery of sensorimotor functions and in counteracting behavioral deficits in case of spinal cord injury (SCI) .
 Gobron et al. (2000) Glia. 32(2):177-91.
 Monnerie, H. et al. (1998) Cell Tissue Res 293(3): 407-18.
 Sakka L et al. (2014 ) PLoS One 25;9(3).
NX210 has been granted Orphan Drug Designation by European Medicine Agency (EMA) for the treatment of spinal cord injury and a Clinical Trial Application (CTA) for a phase I is now authorized by the french and belgian authorities. Our intent is to rapidly initiate this clinical trial for this indication.